Initial results from a First-In-Human Ph1 study in relapsed refractory Acute Myeloid Leukemia (AML) patients treated with BL-M11D1, a novel CD33 antibody-drug conjugate (ADC) REDMOND, Wash., Nov. 26, 2024 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology...
SystImmune, Inc. Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
Seaking AlphaSeeking Alpha / Seaking Alpha 4 hours ago 1 Views
Comments